Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

(2017) Gabriele Gugliotta et al.   HAEMATOLOGICA

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

(2017) Gabriel Etienne et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

(2017) A Hochhaus et al.   LEUKEMIA

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

(2017) Gabriele Gugliotta et al.   HAEMATOLOGICA

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

(2016) Delphine Rea et al.   BLOOD

Moving treatment-free remission into mainstream clinical practice in CML

(2016) Timothy P. Hughes et al.   BLOOD

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

(2016) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival

(2016) Jonathan Douxfils et al.   JAMA Oncology

The impact of dasatinib on pregnancy outcomes

(2015) Jorge E. Cortes et al.   AMERICAN JOURNAL OF HEMATOLOGY

A review of the European LeukemiaNet recommendations for the management of CML

(2015) Michele Baccarani et al.   ANNALS OF HEMATOLOGY

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

(2015) Niklas Gunnarsson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

(2015) A Hochhaus et al.   LEUKEMIA

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

(2015) Jun Imagawa et al.   Lancet Haematology

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors

(2013) Lorenzo Falchi et al.   AMERICAN JOURNAL OF HEMATOLOGY

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience

(2013) Ohad Benjamini et al.   LEUKEMIA & LYMPHOMA

Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience

(2012) H. Kantarjian et al.   BLOOD

Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies

(2011) D. Verma et al.   BLOOD

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

(2010) T. P. Hughes et al.   BLOOD

Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?

(2010) Sheila A Doggrell et al.   EXPERT OPINION ON PHARMACOTHERAPY

Relapse and Late Mortality in 5-Year Survivors of Myeloablative Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia in First Chronic Phase

(2010) John M. Goldman et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Immunolocalization of lingual antimicrobial peptide (LAP) in the bovine mammary gland

(2009) Naoki ISOBE et al.   ANIMAL SCIENCE JOURNAL

Heart failure with preserved versus reduced left ventricular systolic function: A prospective cohort of Shinken Database 2004–2005

(2009) Ayumi Goda et al.   Journal of Cardiology

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

(2009) Michele Baccarani et al.   JOURNAL OF CLINICAL ONCOLOGY

GADD34 suppresses wound healing by upregulating expression of myosin IIA

(2009) Chie Tanaka et al.   TRANSGENIC RESEARCH

The effects of imatinib on pregnancy outcome

(2008) S. M. Pye et al.   BLOOD